Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v8-FR Version v7-EN
Language French English
Date Updated 2020-08-06 2020-08-06
Drug Identification Number 02404761 02404761
Brand name GANCICLOVIR FOR INJECTION GANCICLOVIR FOR INJECTION
Common or Proper name Ganciclovir for Injection Ganciclovir for Injection
Company Name FRESENIUS KABI CANADA LTD FRESENIUS KABI CANADA LTD
Ingredients GANCICLOVIR GANCICLOVIR
Strength(s) 500MG 500MG
Dosage form(s) POWDER FOR SOLUTION POWDER FOR SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS
Packaging size 500mg SD Vial 10mL 500mg SD Vial 10mL
ATC code J05AB J05AB
ATC description DIRECT ACTING ANTIVIRALS DIRECT ACTING ANTIVIRALS
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2020-02-10 2020-02-10
Estimated end date 2020-07-17 2020-07-17
Actual end date 2020-06-29 2020-06-29
Shortage status Resolved Resolved
Tier 3 Status No No
Company comments Fresenius Kabi Canada Ltd. is pleased to advise that replenishment inventories of our Ganciclovir for Injection, 500 mg, 10 mL, SD Vials will be available at all distribution centres , Monday, June 29th, 2020. Fresenius Kabi Canada Ltd. is pleased to advise that replenishment inventories of our Ganciclovir for Injection, 500 mg, 10 mL, SD Vials will be available at all distribution centres , Monday, June 29th, 2020.
Health Canada comments